Companies ›Healthcare ›NACP.NS

NACP.NS — NSE (India) Pharmaceuticals

Nacp.Ns

$152,20

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

4,9 %

ROE

0,3 %

Net margin

0,4 %

Debt / equity

0,45

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

NACP.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

Business. NACP.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

0,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning NACP.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to NACP.NS. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

NACP.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI synthesis

GENERATED

NACP.NS exhibits a capital structure with a debt-to-equity ratio of 0.45, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 1.3, suggesting it can cover its short-term obligations but with limited buffer. However, the company's cash and equivalents amount to only INR 1,000, which is significantly lower than its long-term debt of INR 1,051,945,000, resulting in a negative net cash position.

In terms of profitability, NACP.NS has a return on equity (ROE) of 0.27% and a return on assets (ROA) of 0.15%, both of which are below the industry median for pharmaceutical companies. This suggests that the company is underperforming in generating returns relative to its equity and asset base. The operating margin is 4.9%, which is also below the industry median, indicating that the company is not as efficient in converting revenue into operating profit.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher risk if demand in its primary market declines.

Looking at the growth trajectory, NACP.NS has shown a decline in free cash flow, with a negative value of INR -348,948,000 in the latest reporting period. This is primarily due to a capital expenditure of INR -446,302,000, which has outpaced the operating cash flow of INR 267,521,000. The company's revenue has also remained relatively flat, with no significant growth reported in the latest financial data.

The risk assessment for NACP.NS highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for long-term debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's capital structure and negative free cash flow could lead to increased financial risk in the future.

Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company has not issued any new shares or taken on additional debt in the latest reporting period, and there are no significant regulatory or legal issues disclosed in the available data.

Key takeaways

NACP.NS has a conservative debt-to-equity ratio of 0.45, but its liquidity is medium due to a low cash balance.
The company's ROE and ROA are below industry medians, indicating underperformance in profitability.
NACP.NS has a negative free cash flow, driven by high capital expenditures.
The company's revenue is concentrated in a single segment, increasing its exposure to market-specific risks.
The company's dilution risk is low, but its liquidity risk is medium due to a negative net cash position.

Bull / Bear case

analysis pipeline

— missing data

In focus — financials by report

Valuation

Market price

$152,20

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$2.33B

Net cashⓘ

-$1.05B

Current ratioⓘ

1.3

Debt / equityⓘ

0.5

ROAⓘ

0.1%

ROEⓘ

0.3%

Cash conversionⓘ

4333.0%

CapEx / revenueⓘ

-26.4%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin4,9 %Below median

Net Margin0,4 %Below median

ROE0,3 %Below median

Capex / Rev-26,4 %Bottom quartile

D/E0,45Below median

Cash Conv43,33Best in class

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

NACP.NS Market data — financials · 2026-05-28

Ownership & reference

Insider activity

— missing data

Short positioning

9.7Kshares short+14.3% vs prior

5.9days to cover

71.8%short of daily vol

544fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

NACP.NSCanonical

NSE (India) · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread